Tagrisso (osimertinib) | Friends of Cancer Research

You are here

Tagrisso (osimertinib)

Sponsor: 
AstraZeneca
Indication: 
Adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.
Category: 
Year: 
2020
Date: 
Jul 30th
FDA Status: 
Designation Granted